Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about the study, please email or call 312-355-5112.

A Phase I Trial of Talimogene Laherparepvec for the Treatment of Periotoneal Surface Malignancies (TEMPO)

Sponsor: Dan Blazer III, MD
Principal Investigator: John Stewart IV, MD, MBA

Translate »